Iovance Biotherapeutics Inc

NASDAQ:IOVA 4:00:00 PM EDT

5.53

-0.22 (-3.83%)

6:08:26 PM EDT: $6.31 +0.78 (+14.11%)

Market Cap (Intraday)	1.24B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.22 Million
Adjusted EPS	-$0.57

See more estimates

10-Day MA	$6.18
50-Day MA	$7.06
200-Day MA	$8.88

See more pivots

Iovance Biotherapeutics Inc Stock, NASDAQ:IOVA

825 Industrial Road, Suite 400, San Carlos, California 94070

United States of America

Phone: +1.650.260.7120

Number of Employees: 503

http://www.iovance.com

Description

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.